• Advertise
  • Membership
  • Sign inSUBSCRIBE
Legal Era
X
Sign in
  • Home
  • News
    +
    • From the Courts
    • Policy & Law
    • Supreme Court (India)
    • High Court (India)
    • TAX Updates
    • MARKET WATCH
    • Deal Street
    • Global Insights
    • IBC Cases
    • Hires & Moves
    • IP News
    • Competition Verdict
  • Articles
    +
    • ABOUT THE LAW
    • AWARDS & ACCOLADES
    • Aerospace
    • Agriculture
    • Alternate Dispute Resolution
    • Banking and Finance
    • Bankruptcy
    • Book Review
    • Bribery & Corruption
    • Commercial Litigation
    • Competition Law
    • Conference Reports
    • Consumer Products
    • Contract
    • Corporate Governance
    • Corporate Law
    • Covid-19
    • Cryptocurrency
    • Cybersecurity
    • Data Protection
    • Defence
    • Digital Economy
    • E-commerce
    • Employment Law
    • Energy and Natural Resources
    • Entertainment and Sports Law
    • Environmental Law
    • FDI
    • Food and Beverage
    • Health Care
    • IBC Diaries
    • Insurance Law
    • Intellectual Property
    • International Law
    • Labour Laws
    • Litigation
    • Litigation Funding
    • Manufacturing
    • Mergers & Acquisitions
    • NFTs
    • Privacy
    • Private Equity
    • Project Finance
    • Real Estate
    • Risk and Compliance
    • Technology Media and Telecom
    • Tributes
    • Zoom In
    • Take On Board
    • In Focus
    • Law & Policy and Regulation
    • IP & Tech Era
    • Viewpoint
    • Arbitration & Mediation
    • Tax
    • Student Corner
  • Law Firms
  • In-House
  • Rankings
  • E-Magazine
  • Legal Era TV
  • Events
  • News
    • From the Courts
    • Policy & Law
    • Supreme Court (India)
    • High Court (India)
    • TAX Updates
    • MARKET WATCH
    • Deal Street
    • Global Insights
    • IBC Cases
    • Hires & Moves
    • IP News
    • Competition Verdict
  • Articles
    • ABOUT THE LAW
    • AWARDS & ACCOLADES
    • Aerospace
    • Agriculture
    • Alternate Dispute Resolution
    • Banking and Finance
    • Bankruptcy
    • Book Review
    • Bribery & Corruption
    • Commercial Litigation
    • Competition Law
    • Conference Reports
    • Consumer Products
    • Contract
    • Corporate Governance
    • Corporate Law
    • Covid-19
    • Cryptocurrency
    • Cybersecurity
    • Data Protection
    • Defence
    • Digital Economy
    • E-commerce
    • Employment Law
    • Energy and Natural Resources
    • Entertainment and Sports Law
    • Environmental Law
    • FDI
    • Food and Beverage
    • Health Care
    • IBC Diaries
    • Insurance Law
    • Intellectual Property
    • International Law
    • Labour Laws
    • Litigation
    • Litigation Funding
    • Manufacturing
    • Mergers & Acquisitions
    • NFTs
    • Privacy
    • Private Equity
    • Project Finance
    • Real Estate
    • Risk and Compliance
    • Technology Media and Telecom
    • Tributes
    • Zoom In
    • Take On Board
    • In Focus
    • Law & Policy and Regulation
    • IP & Tech Era
    • Viewpoint
    • Arbitration & Mediation
    • Tax
    • Student Corner
  • Law Firms
  • In-House
  • Rankings
  • E-Magazine
  • Legal Era TV
  • Events

Top Stories

  • Cyril Amarchand Mangaldas advised Viacom 18 on the INR 13,500 crores investment by Bodhi Tree Systems
    Cyril Amarchand Mangaldas advised Viacom
  • Shardul-Amarchand-Mangaldas
    Shardul Amarchand Mangaldas, Veritas
  • Cyril Amarchand Mangaldas advised acquisition of Ambuja Cement and ACC Ltd by Adani Group for USD 10.5 billion
    Cyril Amarchand Mangaldas advised
  • Cyril-Amarchand-Mangaldas
    Cyril Amarchand Mangaldas advised Ayu
  • Supreme-Court
    Supreme Court rules on GST Council
  • Justice-NV-Ramana-&-Tushar-Mehta
    Supreme Court agrees to deliberate on
  • Google-Ads
    Google Ads trademark infringement
  • RazorPay
    Sachin S joins RazorPay as Legal
  • Veritas-AZB-IndusLaw
    Veritas, AZB, IndusLaw, Clifford, and GT
  • Nitin-Gera-&-Shruti-Barua
    L&L Partners advised Honasa Consumer on
Panacea Biotech files suit in Delhi HC against Sanofi for patent infringement
HomeNewsIP News
IP News

Panacea Biotech files suit in Delhi HC against Sanofi for patent infringement

By Legal Era
18 May 2021 8:30 AM GMT

Panacea Biotech files suit in Delhi HC against Sanofi for patent infringement

Panacea Biotech files suit in Delhi HC against Sanofi for patent infringement

Panacea Biotech files suit in Delhi HC against Sanofi for patent infringement A suit has been filed by Panacea Biotech Limited before the Delhi High Court for restraining Sanofi Healthcare India Pvt. Ltd. from marketing Hexavelent vaccine which will infringe Panacea's patent for its fully liquid Whole-Cell Pertussis based fully liquid Hexavalent Vaccine, EasySix. The fight between Sanofi...

ToRead the Full Story, Subscribe to Legal Era

Access the exclusive LEGAL ERAStories,Editorial and Expert Opinion

Subscribe Now
AlreadyaSubscriber?SigninNow
View Plans

Panacea Biotech files suit in Delhi HC against Sanofi for patent infringement

A suit has been filed by Panacea Biotech Limited before the Delhi High Court for restraining Sanofi Healthcare India Pvt. Ltd. from marketing Hexavelent vaccine which will infringe Panacea's patent for its fully liquid Whole-Cell Pertussis based fully liquid Hexavalent Vaccine, EasySix.

The fight between Sanofi and Panacea has been since 2017 before the Indian Patent Office which has also been fought before the Bombay and Delhi High Court in 2018 and 2019. The drug EasySix developed by Panacea Biotech is used to vaccinate against Diphtheria, Tetanus, Whooping Cough, Hepatitis B, Haemophilus influenza type b, and Inactivated Polio (DTwP-HepB-Hib-IPV).

This drug comes in a prefilled syringe and is the first of its kind Whole-Cell Pertussis-based fully liquid Hexavalent Vaccine. The EasySix has been marketed since 2017 and Panacea is planning to make this available to the government for vaccination/immunization domestically and internationally.

Sanofi received the market approval for the Whole-Cell Pertussis-based Hexavalent vaccine (DTwP-HepB-Hib-IPV) by the Drugs Controller General of India. "The suit filed against Sanofi comes at the heels of Sanofi having received marketing approval for a Whole-Cell Pertussis-based Hexavalent vaccine by the Drugs Controller General (India)," Panacea Biotec added. Recently when the matter was listed before the Delhi High Court, Sanofi undertook that it will not manufacture and market product that can infringe amended claims of Panacea patent, IN272351.

As per the Pertussis license is concerned, currently, two types of pertussis vaccine are licensed which are whole-cell pertussis (wP) and acellular pertussis (aP). Comparing both, Whole-Cell immunization has been comparatively effective and inexpensive.

In industrialized countries, aP vaccine has gradually supplanted the use of wP vaccine, nevertheless, the higher cost of development and production cost of aP vaccines made it more costly as compared to the dose of wP vaccine. The efficacy of both aP and wP vaccine remains almost the same, wP vaccine remains the upper choice due to its less cost.

Sanofi will now be providing the argument towards the Panacea Biotech Claims and the suit will follow.

Legal Era

Legal Era

TAGS:
  • Panacea 
  • Sanofi 
  • Delhi High Court 
  • Patent 
  • infringement 
  • Hexavalent vaccine 
  • EasySix 
  • Drugs Controller General of India 
  • Indian Patent Office 
Next Story
Similar Posts
See More
Trending Now
Tax on Alimony

Tax on Alimony

The Hierarchy of Indian Courts

The Hierarchy of Indian Courts

Insolvency Procedure For MSMEs?

Insolvency Procedure For MSMEs?

Cyril-Amarchand-Mangaldas

Cyril Amarchand Mangaldas advised Ayu Health and Vertex

Recommended Articles
Arbitration and Commercial Courts: A Jurisdictional Conflict

Arbitration and Commercial Courts: A Jurisdictional Conflict

Multiplicity of Arbitral Proceedings in India

Multiplicity of Arbitral Proceedings in India

Copyright and Non-Fungible Tokens (NFTs)

Copyright and Non-Fungible Tokens (NFTs)

Renewed Interest in Quincecare Duty of Care in Claims Against Banks

Renewed Interest in Quincecare Duty of Care in Claims

  • News
  • From the Courts
  • Supreme Court (India)
  • High Court (India)
  • Global Insights
  • Deal Street
  • Hires & Moves
  • Refund & Cancellation Policy
  • Articles
  • Zoom In
  • Take On Board
  • In Focus
  • Law & Policy
  • IP & Tech Era
  • Viewpoint
  • Arbitration & Mediation
  • Tax
  • Student Corner
  • Interviews
  • Law Firms
  • E-Magazine
  • Legal Era TV
  • Membership
  • Reader's Feedback
  • Cartoons
  • Subscribe
Follow Us
Subscribe Newsletter
  • 2022© All rights reserved Legal Era Media Group
  • Who We Are
  • Careers
  • Advertise with Us
  • Contact Us
  • Privacy Policy
  • Terms and Conditions
Powered by  Hocalwire
X
X